

## Message from the President



As we turn over another season and enter the fall (in North America), we see activity around our bovine immunotherapy, Amplimune®, start to ramp up. Although Amplimune can be used any time of the year, it's the fall when we see increased use in animals being congregated in

different settings like beef feedlots.

According to bovine veterinary consultant Dr. Marc Campbell, it's like the first day of Kindergarten. The animals are eating different food, are in a different environment, and are with friends that they have never seen before.

We know that both young and mature cattle (dairy or beef) can be negatively affected by stress. Weather, shipping, movement from one setting to another, co-mingling with other animals, etc. can take a toll on the immune system.

A healthy immune system is optimal in the face of both infectious agents and stress.

That's where Amplimune comes into play. It boosts the immune system to be ready to fight when exposure to threats occurs.

Amplimune stimulates both innate immunity (what the animal is born with) and humoral immunity (learned immunity).

At a time when judicious use of antimicrobials (including antibiotics) is being strongly advised to avoid treatment-resistant bacteria, natural products like Amplimune are the perfect alternative.

We encourage you to learn more about our mycobacterium cell wall fraction (MCWF) technology by visiting our website ([www.NovaVive.ca](http://www.NovaVive.ca)).

## Global sarcoid expert joins NovaVive webinar

NovaVive was pleased to welcome Professor Derek Knottenbelt to present a webinar, "Managing Equine Sarcoid Tumors" in June of this year.

Prof. Knottenbelt is a specialist in equine internal medicine and a Diplomat of the European College of Equine Internal Medicine.

He retired from a personal chair in Equine Medicine at the University of Liverpool in 2010 having run a sarcoid referral service for over 20 years. He established Equine Medical Solutions Ltd and offers a consultancy service for vets in equine oncology and other challenging clinical conditions. His main interests are in oncology, ophthalmology, wound management and dermatology. He is the primary author of 10 equine veterinary textbooks and over 100 refereed scientific papers.

In our June webinar, Prof. Knottenbelt discussed the 6 different types of equine sarcoid, noting some of these have



sub-types. An individual horse can have a continuum of tumor types that can progress. He emphasized that equine sarcoids are a very serious disease. He has personally treated more than 149,000 cases in his 55+ year career using 20 or 30 different treatment modalities.

During the webinar, Prof. Knottenbelt reviewed the various treatment options in detail. Surgery is often the first intervention veterinarians will use, and Prof. Knottenbelt agreed that surgery is good,

but not on its own. A secondary treatment modality is often necessary.

Regulator-approved in the USA and Canada, NovaVive's Immunocidin® Equine is also available to the UK market through special import permit.

Prof. Knottenbelt has used Immunocidin Equine immunotherapy to treat approximately 200 sarcoid cases. He estimates that he has seen an 80% response rate in those cases. He recommends using very fine needles dispensing product as the needle is withdrawn through the tumor. He follows a grid pattern for best effect.

Prof. Knottenbelt describes this product as "a major improvement in the immunotherapy of sarcoids that should be used much more. This is a really good advance. It is a very worthwhile material."

# Employee Profile: Lynn Bailes

We often reference our valued employees, but we don't often talk about them in detail. We're pleased to introduce a new feature in our quarterly newsletter focused on our hardworking employees. In this first edition, we learn more about Lynn Bailes, our Production Facility and Compliance Manager in Athens, GA, USA.

**Q:** How long have you worked with NovaVive?

**A:** I've worked with NovaVive for 10 years.

**Q:** What did you do before joining NovaVive?

**A:** I manufactured the MCWE product line for Vetrepharm Research then Bioniche Animal Health and now NovaVive USA for the last 30 years. I started with Vetrepharm on September 19, 1994.

**Q:** What is your background/education?

**A:** I have a Bachelor of Science in Agricultural Economics from the University of Georgia with a minor in Animal

Science. I have 36 years experience working in the veterinary biologics industry.

**Q:** What do you like most about your job?

**A:** I enjoy talking with veterinarians and dog/horse owners to answer their questions. It's always nice to help dog/horse owners and to give them some amount of hope.

**Q:** What makes you most proud about your work?

**A:** I am most proud of the quality of product that is made in this facility. The customers always receive an effective and safe product they can count on.

**Q:** What is the greatest challenge at work?

**A:** My greatest challenge is not taking the job home with me.



**Q:** If you were to have done something else, career-wise, what would it have been?

**A:** I always thought I would have made a great nurse.

**Q:** What is your favourite hobby in your down time?

**A:** Playing with my grandson.

**Q:** What is something surprising that most people don't know about you?

**A:** I honestly can't think of anything surprising that most people don't know about me. I'm an open book!


## In memory of Kipenzi the giraffe

We were sad to hear about the passing of Kipenzi the Masai giraffe at Seneca Park Zoo in Rochester, NY and we offer our condolences to the staff at the Zoo.

Kipenzi had been undergoing experimental treatment with Immunocidin<sup>®</sup>, our anticancer immunotherapy, to treat a squamous cell carcinoma tumor in her jaw. She received topical, then oral treatments.

"Kipenzi lived much longer than we had expected," said Zoo veterinarian Dr. Chris McKinney. "Our staff is very happy for the time we were able to have with her."

Immunocidin is regulator-approved for the treatment of canine mammary cancer, but is undergoing further research in other tumor types and species.



## About Equimune<sup>®</sup>

Equimune<sup>®</sup> is a standalone treatment that jump starts the immune system to help resolve Equine Respiratory Disease Complex (ERDC).



It is regulator-approved in the USA, Australia and New Zealand for intravenous administration. It will stimulate the innate and specific immune responses, as needed, for several days.

In the early stages of a viral infection, Equimune:

- ◆ reduces the time available for viral replication
- ◆ reduces the number of tissue cells affected
- ◆ reduces the degree of cellular damage
- ◆ reduces the duration of clinical signs and physiological abnormalities